Key Players
Competitive Landscape
The diabetic sarcopenia nutrition market has large medical-nutrition companies along with metabolic nutrition and concentrated-protein specialists. Abbott and Fresenius Kabi provide diabetes-specific nutrition having measured energy and protein. Nestlé Health Science and Danone Nutricia have wider clinical and home channels. Meiji and Ajinomoto add carbohydrate and amino-acid formulation experience, whereas Morinaga Milk Industry and Medtrition participate through older-adult research and small-volume protein servings. Increasing competition is expected to focus on carbohydrate design, protein amount, serving volume, swallowing suitability and availability after discharge. Therefore, mentioning a higher number of nutrients on the product pack will not alone decide the product preference.
Companies are also increasing work around nutrition science, portfolio integration and patient support beside the product. Nestlé Health Science announced university collaborations in November 2025, while Nestlé combined Nutrition and Health Science from April 2026. Danone expanded diabetes-care communication in November 2025 for connecting targeted nutrition with easier daily use. These developments show that companies are strengthening evidence, guidance and channel continuity together. This is expected to help a formula start in hospital and continue through home, retail or online purchase, creating regular demand instead of only one-time product trial.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| In April 2026, Nestlé combined Nutrition and Nestlé Health Science into one business. | Specialized nutrition needs faster portfolio decisions. | Clinical and consumer nutrition management is becoming more integrated. | Shared channels can improve access from professional recommendation to home purchase. |
| In November 2025, Nestlé Health Science announced nutrition-science collaborations with universities in the USA and Australia. | Companies need stronger evidence for targeted nutrition use. | Research partnerships are widening beyond internal laboratories. | New evidence can support formulation choices and professional education. |
| In November 2025, Danone expanded its diabetes-care communication around targeted nutrition and daily accessibility. | People with diabetes need practical nutrition support beside medicines. | Suppliers are pairing products with clearer use guidance. | Simpler guidance can support continued use outside clinical settings. |
| In September 2025, Nestlé Health Science opened applications for health-economics and outcomes-research grants. | Payers and providers require evidence beyond nutrient composition. | Nutrition companies are adding outcomes and access research. | Economic evidence can strengthen institutional review and coverage discussions. |
Source: Future Market Insights, Diabetic Sarcopenia Nutrition Market Report, 2026-2036.
Abbott, Nestlé Health Science, Danone Nutricia and Fresenius Kabi compete through wider medical-nutrition systems. Meiji, Ajinomoto, Morinaga Milk Industry and Medtrition compete through metabolic formulation, amino-acid knowledge, older-adult research or compact protein delivery.
Who leads the diabetic sarcopenia nutrition market?
Public evidence does not confirm one revenue-share leader. The competition remains divided between broad clinical-nutrition companies and narrower metabolic or protein specialists.
Which companies provide diabetes-specific nutrition capability?
Abbott, Nestlé Health Science, Meiji, and Fresenius Kabi have documented diabetes-oriented nutrition products or formulation capability.
Which companies add muscle-focused formulation capability?
Abbott, Ajinomoto, Fresenius Kabi, Morinaga Milk Industry, and Medtrition have documented protein, amino-acid, or muscle-related capability.
What should buyers assess before selecting a product?
Buyers are expected to assess carbohydrate design, protein amount, serving volume, renal fit, swallowing need, product evidence and the availability after discharge.
Representative Company Overview
| Company | Positioning | Verified market-relevant capability |
|---|---|---|
| Abbott | Global medical-nutrition platform | Ensure Diabetes Care reformulation launched in November 2025. |
| Nestlé Health Science | Global medical and consumer nutrition platform | Diabetes-oriented oral nutrition and home-access channels. |
| Danone Nutricia | Global specialized-nutrition platform | Kate Farms majority acquisition completed in July 2025. |
| Meiji | Japan-based medical-nutrition supplier | Carbohydrate-adjusted clinical nutrition portfolio. |
| Ajinomoto | Global amino-acid specialist | Leucine-rich essential amino-acid nutrition platform. |
| Fresenius Kabi | Global clinical-nutrition supplier | Diben 2 KCAL Drink provides 400 kcal and 20 g protein per 200 ml. |
| Morinaga Milk Industry | Older-adult nutrition researcher | Protein-status research and clinical-nutrition activity. |
| Medtrition | Clinical protein specialist | ProSource Cup launched in March 2025 with 20 g protein in two ounces. |
Research Methodology
The competitive review uses official company releases, product documents, current clinical guidance and national health sources published or updated from January 2025 onward. Company placement is based on documented product, ingredient and channel capability and does not represent market-share ranking. The forecast covers 2026 to 2036 within the defined product boundary. Segment shares, country growth rates and market values are proprietary analytical estimates.
